Breaking News, Collaborations & Alliances

BMS, KineMed Extend Alzheimer’s Pact

Bristol-Myers Squibb and KineMed, Inc. have extended their research collaboration in the area of Alzheimer’s disease and other neurodegenerative conditions.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and KineMed, Inc. have extended their research collaboration in the area of Alzheimer’s disease and other neurodegenerative conditions. Under the extension, BMS has non-exclusive license to KineMed’s technologies to identify and characterize biomarkers for Alzheimer’s disease in cerebrospinal fluid. “Understanding what is going on in the living brain is key to drug development in neurodegenerative diseases. We can measure fundamental brain processes in a living person th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters